<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945148</url>
  </required_header>
  <id_info>
    <org_study_id>2019_0007</org_study_id>
    <nct_id>NCT04945148</nct_id>
  </id_info>
  <brief_title>Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tailored approaches targeting crucial oncogenes and pathways have shown successful results in&#xD;
      a number of cancer types and offer exciting perspective in neuro-oncology. IDH (Isocitrate&#xD;
      dehydrogenase) wild-type (IDHwt) glioblastoma (GBM) (10%) present a unique and homogenous&#xD;
      energetic metabolism which is specifically dependent on the oxidative phosphorylation&#xD;
      (OXPHOS) rather than on the aerobic glycolysis. OXPHOS+ IDHwt GBMs overexpress mitochondrial&#xD;
      markers and can be specifically inhibited by mitochondrial inhibitors in vitro and in vivo.&#xD;
&#xD;
      Metformin is an oral inhibitor of mitochondrial complex I and is a widely used drug in&#xD;
      diabetic and non-diabetic patients, safe and well tolerated in association with radiotherapy&#xD;
      and chemotherapy.&#xD;
&#xD;
      Basing on drastic effect, the investigators have observed in vivo (reduction of &gt;50% of tumor&#xD;
      growth) and hypothesize that metformin could be specifically efficient to treat up-front&#xD;
      patients affected by OXPHOS+ GBM, in association with the standard first-line treatment with&#xD;
      radiotherapy and temozolomide (RT-TMZ).&#xD;
&#xD;
      The investigators set up a dedicated molecular analysis including RNA assay and expression of&#xD;
      OXPHOS markers for formalin-fixed paraffin-embedded tumors (FFPE), which allows to detect&#xD;
      OXPHOS+ GBM at diagnosis.&#xD;
&#xD;
      Here a phase II, open label, non-randomized multicenter trial including five French&#xD;
      neurooncology centers (H. Foch-Suresnes, Pitié-Salpêtrière-Paris, Saint Louis-Paris, Lyon,&#xD;
      Marseille) and one in Italy (Istituto Besta, Milan) is proposed.&#xD;
&#xD;
      Newly diagnosed IDH wild-type GBM patients with the OXPHOS+ signature will be eligible for&#xD;
      inclusion in this trial. The investigators expect to screen 640 patients and to include 64&#xD;
      patients over a period of 24 months with 24 months of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Metformin (1500 to 3000mg/day) in addition to Stupp protocol, starting 7 days before the start of the standard radiotherapy (RT, 60Gy/6 weeks), concomitant Temozolomide (TMZ) chemotherapy (75mg/m²/day), and adjuvant TMZ (150-200 mg/m2/ 5 days) + metformin will follow onwards until the 12th cycle of TMZ</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessement of Progression Free Survival (PFS) of patients with newly-diagnosed IDH wild-type OXPHOS + GBM (either with or without FGFR3-TACC3 gene fusion) treated with RT plus TMZ combined with metformin</measure>
    <time_frame>During the 24 months of follow-up</time_frame>
    <description>Progression free survival (PFS) estimated by the RANO (Response Assesment in Neuro Oncology) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessement of the Overall survival (OS) of treated patients</measure>
    <time_frame>During the 24 months of follow-up</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessement of the Overall Response rate (ORR)</measure>
    <time_frame>During the 24 months of follow-up</time_frame>
    <description>Overall response rate (ORR) estimated by the RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessement of the the safety of metformin in association with concomitant RT-TMZ</measure>
    <time_frame>During the 24 months of follow-up</time_frame>
    <description>Type, frequency, and severity (grade III and IV toxicity) of Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessement of the the tolerability of metformin in association with concomitant RT-TMZ</measure>
    <time_frame>During the 24 months of follow-up</time_frame>
    <description>Dose interruptions, reductions and dose intensity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Glioblastoma, IDH-wildtype</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have been selected with an OXPHOS+ status, will start standard radiotherapy (RT, 60Gy/6 weeks), concomitant TMZ chemotherapy (75mg/m²/day), and metformin by 7 weeks after surgery and adjuvant TMZ + metformin will follow onwards until the 12th cycle of TMZ. Patients still in remission after this time-point will continue metformin alone until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation IMRT</intervention_name>
    <description>2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed informed consent for selection and treatment phase obtained from&#xD;
             the patient/legal representative prior to performing any protocol-related procedures,&#xD;
&#xD;
          2. Patients must be willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits, and examinations including&#xD;
             follow-up,&#xD;
&#xD;
          3. Newly-diagnosed histologically-confirmed supra-tentorial IDHwt glioblastoma (Grade IV&#xD;
             malignant glioma by World Health Organization, including gliosarcoma),&#xD;
&#xD;
          4. OXPHOS+ subtype by the central laboratory&#xD;
&#xD;
          5. No prior treatment for GBM other than surgery,&#xD;
&#xD;
          6. Substantial recovery from surgical resection, no major ongoing safety issues (eg,&#xD;
             infection requiring I.V. antibiotics) following surgery,&#xD;
&#xD;
          7. Without corticosteroids or with stable dose of corticosteroids (ie ≤ dexamethasone 6&#xD;
             mg, methylprednisolone 30 mg or prednisone 38 mg),&#xD;
&#xD;
          8. ECOG (Eastern Cooperative Oncology Group) performance status 0-2,&#xD;
&#xD;
          9. Able to receive concomitant radio-chemotherapy according to the Stupp protocol (60Gy)&#xD;
             based on investigator judgment,&#xD;
&#xD;
         10. Adequate bone marrow and normal hepatic function,&#xD;
&#xD;
         11. Creatinine clearance ≥ 30 mL/min (between 30 and 50 ml/min, patients will be&#xD;
             prescribed no more than 1500mg of metformin),&#xD;
&#xD;
         12. Able to start RT within 7 weeks after histological diagnosis,&#xD;
&#xD;
         13. Patients must have life expectancy ≥ 16 weeks,&#xD;
&#xD;
         14. Patients affiliated to an appropriate health insurance system,&#xD;
&#xD;
         15. Age ≥ 18 years old,&#xD;
&#xD;
         16. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to the&#xD;
             start of study drug,&#xD;
&#xD;
         17. Women of childbearing potential (WOCBP) must agree to follow instructions for&#xD;
             method(s) of contraception from the signing of the informed consent and continue&#xD;
             throughout period of taking study treatment and for 30 days after last dose of study&#xD;
             drug (duration of ovulatory cycle) plus the time required for the investigational drug&#xD;
             to undergo five half-lives (both TMZ and metformin). The terminal half-life of&#xD;
             temozolomide is 1.8 hours. The terminal half-life for metformin is 6.5 hours.&#xD;
&#xD;
         18. Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception throughout the period of taking study treatment and for 6&#xD;
             months plus the time required for the investigational drug to undergo five half-lives&#xD;
             (both TMZ and metformin). The terminal half-life of temozolomide is 1.8 hours. The&#xD;
             terminal half-life for metformin is 6.5 hours.&#xD;
&#xD;
         19. White blood cells (WBC) ≥ 2000/μL&#xD;
&#xD;
         20. Neutrophils ≥ 1500/μL,&#xD;
&#xD;
         21. Platelets ≥ 100 x103/μL,&#xD;
&#xD;
         22. Hemoglobin ≥ 9.0 g/dL,&#xD;
&#xD;
         23. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 30 mL/min (using the&#xD;
             Cockcroft-Gault formula) Female CrCl = (140-age in years) x weight in kg x 0.85 72 x&#xD;
             serum creatinine in mg/dL Male CrCl = (140-age in years) x weight in kg x 1.00 72 x&#xD;
             serum creatinine in mg/dL&#xD;
&#xD;
         24. Aspartate AminoTransferase (AST) ≤ 3.0 x ULN,&#xD;
&#xD;
         25. Alanine Aminotransferase (ALT) ≤ 3.0 x ULN,&#xD;
&#xD;
         26. Total Bilirubin ≤ 1.5 x ULN (except patients with Gilbert Syndrome who may have a&#xD;
             total bilirubin &lt; 3.0 x ULN).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment for GBM (other than surgical resection) including Gliadel wafer,&#xD;
&#xD;
          2. Patients with second primary cancer, except: adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumors&#xD;
             curatively treated with no evidence of disease for ≥ 5 years,&#xD;
&#xD;
          3. Any known metastatic extracranial or leptomeningeal disease,&#xD;
&#xD;
          4. IDH mutant,&#xD;
&#xD;
          5. Secondary GBM (ie, progression from prior low-grade or anaplastic glioma),&#xD;
&#xD;
          6. Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the patient to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results,&#xD;
&#xD;
          7. Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study medication&#xD;
             (inflammatory bowel disease, major bowel resection),&#xD;
&#xD;
          8. Pregnant or breast-feeding women,&#xD;
&#xD;
          9. Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV) and are receiving anti-viral therapy,&#xD;
&#xD;
         10. Patients with known active hepatitis (i.e., Hepatitis B Virus (HBV) or Hepatitis C&#xD;
             Virus (HCV)),&#xD;
&#xD;
         11. Patients with a known hypersensitivity to metformin and temozolomide or any of the&#xD;
             excipients of the products,&#xD;
&#xD;
         12. Patients with severe renal insufficiency ie, CrCl &lt; 30 mL/min (who should not receive&#xD;
             contrast materials),&#xD;
&#xD;
         13. History or evidence upon physical/neurological examination of other central nervous&#xD;
             system condition (eg, seizures, abscess) unrelated to cancer, unless adequately&#xD;
             controlled by medication or considered not potentially interfering with protocol&#xD;
             treatment,&#xD;
&#xD;
         14. Patients unable (eg, due to pacemaker or Implantable Cardioverter Defibrillator (ICD)&#xD;
             device) or unwilling to have a contrast-enhanced MRI of the head,&#xD;
&#xD;
         15. Any acute medical condition that may impair renal function such as dehydration, severe&#xD;
             infection, shock,&#xD;
&#xD;
         16. Any disease which may cause tissue hypoxia such as decompensated heart failure,&#xD;
             respiratory failure, recent myocardial infarction&#xD;
&#xD;
         17. Diabetic precoma&#xD;
&#xD;
         18. Acute metabolic acidosis,&#xD;
&#xD;
         19. Alcohol intoxication and Alcoholism,&#xD;
&#xD;
         20. Persons protected by a legal regime (guardianship, trusteeship),&#xD;
&#xD;
         21. Prisoners or patients who are involuntarily incarcerated,&#xD;
&#xD;
         22. Patients who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Luisa DI STEFANO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foch Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Luisa DI STEFANO, MD</last_name>
    <phone>01 46 25 37 22</phone>
    <phone_ext>00 33</phone_ext>
    <email>al.di-stefano@hopital-foch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth HULIER-AMMAR, PhD</last_name>
    <phone>01 46 25 11 75</phone>
    <phone_ext>00 33</phone_ext>
    <email>drci-promotion@hopital-foch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foch Hospital</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts De Seine</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Luisa DI STEFANO, MD</last_name>
      <phone>01 46 25 37 22</phone>
      <phone_ext>0033</phone_ext>
      <email>al.di-stefano@hopital-foch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <state>Lyon</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François DUCRAY, PUPH</last_name>
      <email>francois.ducray@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timone Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CHINOT, PUPH</last_name>
      <email>olivier.chinot@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine CARPENTIER, PUPH</last_name>
      <email>antoine.carpentier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc SANSON, PUPH</last_name>
      <email>marc.sanson@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marica EOLI, MD</last_name>
      <email>marica.eoli@istituto-besta.it</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>FGFR3-TACC3</keyword>
  <keyword>Metformin</keyword>
  <keyword>Radio-chemotherapy</keyword>
  <keyword>OXPHOS+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

